Request Trial
shutterstock-182705003
Morganka / Shutterstock.com
29 October 2014Americas

TapImmune: tapping into innovative cancer treatments

In just five years Glynn Wilson, chief executive of TapImmune, estimates the Seattle-based company will be worth more than a $1 billion. It’s a big claim to make for a company that currently is not making money but Wilson sees no reason why it can’t aim for the top.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
WATCH: Interview with Mythili Markowski, director at Regeneron
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.
Americas
Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’
7 May 2026   A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.
Americas
US judge allows rare patent defence in ‘world’s smallest heart pump’ suit
5 May 2026   J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Europe
WIPR debuts Global In-House Elite 2026
26 March 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026

More features

WATCH: Interview with Mythili Markowski, director at Regeneron
Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’
Kilpatrick adds tech patent litigator and China expert to Chicago office
US judge allows rare patent defence in ‘world’s smallest heart pump’ suit
WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular
Brussels under scrutiny for IP policy as US flags risks to innovation
From the courtroom: Hikma v Amarin SCOTUS oral arguments
Report: 85% of in-house counsel want IP service providers to embrace AI